Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Mediahype van invloed op keuzes bij adjuvante behandeling melanoom?
apr 2019 | Dermato-oncologie, Immuuntherapie